Escitalopram for the Treatment of Obsessive Compulsive Disorder (OCD)

• Status: Completed
• Trial end date: 2007-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the efficacy of Escitalopram in the treatment of obsessive compulsive disorder and to determine the optimal treatment dose.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Massachusetts General Hospital
• Collaborator: Forest Laboratories
• Treatments: Citalopram; Dexetimide

Criteria

Inclusion Criteria:

• Diagnosis of OCD by DSM-IV

• Age 18-65

• Y-BOCS greater than 20

• Written informed consent

• Females of childbearing potential must have a negative serum or urinary beta-HCG test.

Exclusion Criteria:

• Pregnant women or women of childbearing potential who are not using a medically accepted means of contraception.

• Patients who, in the investigator's judgement, pose a serious suicidal or homicidal risk.

• Serious or unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic, or hematologic disease. Patients on anticoagulant therapy.

• History of seizure disorder

• Comorbid bipolar disorder, psychosis, organic mental disorder, or developmental disorder

• If there is a history of substance abuse, patients in remission at least 6 months.

• Currently being treated with behavioral therapy, specifically exposure and response prevention, for OCD.

• Other medications for medical disorders that may interfere with escitalopram

• Current major depression or prescribed an antidepressant for major depression within the past 12 months.

• Taken an SSRI medication within 2 weeks of beginning the study (4 weeks for fluoxetine).

• More than 1 adequate trial (at least 10 weeks at maximally tolerated dose) with another SSRI in the past.